MFN Drug Policy Cuts US Costs; It May Block Europe's First Sjögren's Therapy
· techtimes.com · popularity 19/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Novartis CEO Vasant Narasimhan said bypassing European government health systems for new drug launches is 'not off the table,' warning of significant access delays beginning 2027 as US Most Favored Nation drug pricing forces pharmaceutical companies to choose between US compliance and EU patient access.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.